HSA Approves New JAK inhibitor Abrocitinib (Cibinqo) For The Treatment of Atopic Dermatitis

Share on email
Share on print
Share on whatsapp

The disease burden and current treatment landscape
Atopic dermatitis (AD), or eczema, is the most common skin disorder in Singapore and is estimated to affect 20% of children and 11% of adults in

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading